Brian Cheng
Stock Analyst at JP Morgan
(0.95)
# 3,851
Out of 4,984 analysts
61
Total ratings
39.13%
Success rate
-15.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $70 | $61.00 | +14.75% | 1 | Sep 18, 2025 | |
| PGEN Precigen | Upgrades: Neutral | n/a | $3.82 | - | 3 | Aug 15, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $40 → $37 | $15.11 | +144.87% | 3 | Aug 12, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $8.99 | +144.72% | 3 | Aug 7, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $1.13 | - | 4 | Aug 4, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $37.72 | +8.70% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $38.95 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $59.22 | -3.75% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $12.41 | +4.75% | 4 | Feb 28, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $2.72 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 | $15.87 | +13.42% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $9.25 | +202.70% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $4.37 | +655.15% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.88 | +219.15% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $7.15 | +1,648.25% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $15.28 | -1.83% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.68 | +1,967.34% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.25 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.76 | +689.27% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.37 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.07 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $18.05 | +370.91% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.70 | +172.73% | 1 | Aug 3, 2021 |
CRISPR Therapeutics AG
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $61.00
Upside: +14.75%
Precigen
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $3.82
Upside: -
Immunovant
Aug 12, 2025
Maintains: Overweight
Price Target: $40 → $37
Current: $15.11
Upside: +144.87%
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $8.99
Upside: +144.72%
Allogene Therapeutics
Aug 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $37.72
Upside: +8.70%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $38.95
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $59.22
Upside: -3.75%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $12.41
Upside: +4.75%
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.72
Upside: -
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $15.87
Upside: +13.42%
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $9.25
Upside: +202.70%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $4.37
Upside: +655.15%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.88
Upside: +219.15%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $7.15
Upside: +1,648.25%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $15.28
Upside: -1.83%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.68
Upside: +1,967.34%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.25
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.76
Upside: +689.27%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.07
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $18.05
Upside: +370.91%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.70
Upside: +172.73%